Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposideは一種のポドフィロトキシン(podophyllotoxin)半合成の派生物ですが、トポイソメラーゼ(topoisomerase)IIを抑制することを通じて、DNA合成を抑制します。

サイズ 価格(税別) 在庫  
JPY 15106.00 あり
JPY 11620.00 あり
JPY 46480.00 あり
JPY 114540.00 あり
JPY 164340.00 あり

カスタマーフィードバック(5)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposideは一種のポドフィロトキシン(podophyllotoxin)半合成の派生物ですが、トポイソメラーゼ(topoisomerase)IIを抑制することを通じて、DNA合成を抑制します。
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NFnlWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjqR2V4UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NH;DN4ozPTl4MEK4Ni=>
KellyCis83 M320TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqZWpKUUN3ME2wMlE36oDLwsJihKkxNjB{IN88US=> NFnkV2szPTl4MEK4Ni=>
SK-N-AS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMkVihKnDueLCiUCuNFMh|ryP NEDX[HozPTl4MEK4Ni=>
SK-N-ASCis24 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;temlEPTB;MD61O-KBkcLz4pEJNE4yOSEQvF2= MUGyOVk3ODJ6Mh?=
U87 NW\KWINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLw[XY5OC13MDFOwG0> MYG0PEBp NGLmT4xl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= NE\MUWgzPTd3MEK3Ny=>
HCT116 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvQR3YxNjVvMj61JO69VQ>? NVfQdVBOPDkEoHlCpC=> MWjJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? NWnUfJVZOjV5NE[3OlM>
HT-29 NGDocodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XubVAvPS1{LkWg{txO MoLxOFjDqGkEoB?= MmTOTWM2OD15LkNCpOKyyqBzLkC0xsDPxE1? MYiyOVc1Pjd4Mx?=
Caco2 M4rn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnZNE42NTJwNTFOwG0> MWq0POKhcMLi MoXLTWM2OD15LkK2xsDDucLiMT62POKh|ryP M{DQb|I2PzR4N{[z
COLO 205 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHYeINVOC53LUKuOUDPxE1? MUG0POKhcMLi NWDSd45TUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN NYK3dopKOjV5NE[3OlM>
SW480 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHuXlMxNjVvMj61JO69VQ>? NFXDWGU1QMLiaNMg MUDJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? NEfNR|QzPTd2Nke2Ny=>
HEK293T M37oVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnrWpdqOS13IN88US=> NYHoZldvPDkEoHlCpC=> M{LYTmlEPTB;Mj60NuKhyrIEoECuNFXDqM7:TR?= M2fmVVI2PzR4N{[z
Hep3B  M{L2dmZ2dmO2aX;uJGF{e2G7 M1zH[FExKM7:TR?= M3jCU|Q5yqCqwrC= Mn3OdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> MYiyOVY{OzV4NB?=
Hep3B  NXjrZZN6TnWwY4Tpc44hSXO|YYm= M3rTcFAvOS1zMDFOwG0> NYPjc5hEOjRiaB?= MWLzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NGewV4kzPTZ|M{W2OC=>
HEK293 NVfjd2dXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOyVlI6UUN3ME23MlE1yqEEsdMgNE4{PsLizszN M2i4SVI2PjB|MUKy
DU145 NU\MT3E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwMklCpOKyyqByLkC0xsDPxE1? M2TkN|I2PjB|MUKy
HCT15 NFviPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Kwe2lEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= NF;EOo8zPTZyM{GyNi=>
T47D NGXKSHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL1TWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP NWTreYJkOjV4MEOxNlI>
SMMC-7721 M1nsN2Z2dmO2aX;uJGF{e2G7 NHfJR3M1OCEQvF2= NHTXPVc1QCCq NFT4T41FVVOR NVHhSGc{cW6mdXPld{DPu0h{QWig[o9kcSCob4LtZZRqd25? MVyyOVU1PDN4MR?=
MDA-MB-231 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jTTlczyqCq M4fV[GlEPTB;MkGuNuKhyrIEoESuNuKh|ryP Mlz3NlU1QDZ{MUm=
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPjXFM4OsLiaB?= MXzJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MXuyOVQ5PjJzOR?=
Jurkat MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK3NuKhcA>? MXjJR|UxRTFwMtMgxtHDqDFwNdMg{txO MX6yOVQ5PjJzOR?=
HeLa NVWxOlU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi3NuKhcA>? MkHnTWM2OD1|LkpCpOKyyqB{LkRCpO69VQ>? M4jKN|I2PDh4MkG5
MCF7  M3T0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj3OU0yODBizszN NFq2UXg4KGR? MnLBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnO5NlU1PzJ4MUm=
K562 NWe1[4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L3XlczyqCq Ml\oTWM2OD1yLkK5xsDPxE1? NYHve3NuOjV{OEK2OVM>
K/VP.5 NGHOclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILWfWs4OsLiaB?= NHjQVGxKSzVyPUSuPeKh|ryP M2PFSFI2Ojh{NkWz
SH-EP  M{j3[GZ2dmO2aX;uJGF{e2G7 NWjHNld3OjEEoN88[{9udA>? NGTXN2ozPMLiaB?= M2Gxb4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= M1HQeVI2OjZzOUix
SCC25 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfsTnczPMLiaB?= M{exPGlEPTB;NEOuN:KhyrIEoEGuNVLDqM7:TR?= MoDCNlUzOjB5Mkm=
CAL27 NEPIZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DxeFI1yqCq NEjtWZlKSzVyPUWyMlHDqMLzwrCxMlA6yqEQvF2= MV:yOVIzODd{OR?=
FaDu NEjIVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[3NlTDqGh? NXL5d5R[UUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> MVGyOVIzODd{OR?=
SCC25 NH3qVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fDb|Q5yqCq MnOwTWM2OD1{MD64OuKhyrIEoEGuNFfDqM7:TR?= NGfNbG4zPTJ{MEeyPS=>
CAL27 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm0POKhcA>? MnHRTWM2OD1zOD6yOOKhyrIEoEGuNVXDqM7:TR?= Mmn5NlUzOjB5Mkm=
FaDu MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;EPVduPDkEoHi= M13kUWlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= NELBRo8zPTJ{MEeyPS=>
SCC25 NXmzUJRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NuKhcA>? MmLMTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP M3K2UlI2OjJyN{K5
CAL27 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TlPFczyqCq M3HiSWlEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= M3\TTVI2OjJyN{K5
FaDu NETuN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe3NuKhcA>? M2XVO2lEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= NIfBUXYzPTJ{MEeyPS=>
MCF-7 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P2flQ5yqCqwrC= MX;EUXNQ MnP4TWM2OD15LkNCpOKyyqByLklCpO69VQ>? NV7sUXdZOjV{MU[zO|g>
T-47D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYq0POKhcMLi NGXDcYxFVVOR MXHJR|UxRTdwN9MgxtHDqDBwN9Mg{txO Mn7FNlUzOTZ|N{i=
MDA-MB-231 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j4bVQ5yqCqwrC= NGfFUpdFVVOR NILpOYpKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= M37FRVI2OjF4M{e4
DU145 M1uwdGFxd3C2b4Ppd{BCe3OjeR?= NGSyS2oyOC1zMECg{txO MWi4JIg> MYrEUXNQ MlfrbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MYeyOVE1QTZ6MR?=
DU145 stem-like NX6zb5hoSXCxcITvd4l{KEG|c3H5 NYHFd4NJOTBvMUCwJO69VQ>? MXG4JIg> M4LBU2ROW09? MlTtbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3\Z[|I2OTR7Nkix
DU145 MmLQSpVv[3Srb36gRZN{[Xl? MX[xNE0yODBizszN MkTxNkBp NHTMPYhFVVOR MoTFbY5kemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGGwZDDk[YNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUPyfmU3OjVzNEm2PFE>
DU145 stem-like NWPhO2NjTnWwY4Tpc44hSXO|YYm= MkGzNVAuOTByIN88US=> NHzOfWIzKGh? NVHZTIt2TE2VTx?= NVXPS3ZRcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFX2b2ozPTF2OU[4NS=>
UW228-3 M2\E[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMlAyNTNyMDFOwG0> M3X0WlQ5KGh? M1Sx[WROW09? NXK5cXdUUUN3ME2wMlk6yqEQvF2= MXWyOVEyQTF6NR?=
NSCs NX\HfJprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L5NFAvODFvM{CwJO69VQ>? NFH1Nlg1QCCq MUnEUXNQ MUPJR|UxRTBwMz2zxsDPxE1? M3exN|I2OTF7MUi1
MKL-1  NISxfZVHfW6ldHnvckBCe3OjeR?= MnjMNVAuOTByMDDuUS=> MW[0JIQ> NH[xfo1qdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MYOyOVEyPjd3NB?=
MCF7 EV M1L4dmZ2dmO2aX;uJGF{e2G7 MV6xNE0yODBizszN M{DFSVLjiImq M2nYVIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ NYXyNllDOjVyOEiyNFM>
MCF 7BMI1 M4rxNGZ2dmO2aX;uJGF{e2G7 M1PORVExNTFyMDFOwG0> NHfKN3Yz6oDLaB?= MYrpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MYCyOVA5QDJyMx?=
MCF7 EV NXnURVROTnWwY4Tpc44hSXO|YYm= M{LRUFExNTFyMDFOwG0> Mo\UNwKBkWh? MknFSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NW\uXnpwOjVyOEiyNFM>
MCF7 BMI1 MVrGeY5kfGmxbjDBd5NigQ>? MY[xNE0yODBizszN Mke2NwKBkWh? MmXZSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u NHPEbXkzPTB6OEKwNy=>
HepG2 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnEUXNQyqB? NYXlR2llUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> M1vUVlI2ODd6M{Gx
MOLT-3 NX7FfG1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor3SG1UV8Li M1;4eWlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MYWyOVA4QDNzMR?=
HT1080 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDCNU0yODBizszN MVG0M|I1NzR6IHi= MYDEUXNQyqB? M1jqd4lv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= M2juT|I2ODd6ME[0
HT1080 NW\hWlBQTnWwY4Tpc44hSXO|YYm= MUmwMlAxODFvMUCwJO69VQ>? M4LUTlEuOjRiaB?= M13lUGROW00EoB?= NH3Wd|BqdmS3Y3XzJJAueDV|KIPldlE2MSCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MWSyOVA4QDB4NB?=
HT1080 NX:zcXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniZmRHOC5yMECxMVExOCEQvF2= M3PyNFI1KGh? NVLZSJluTE2VT9Mg MWrjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| NV;wbIU3OjVyN{iwOlQ>
HD-MY-Z NIe2S45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H6dFI1NzR6L{eyJIg> NVrtO|B7UUN3MP-8olExOCEQvF2= MUOyOVA1QDJ|Nh?=
DOHH-2 NUjZOpVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13mUVI1KGh? MXLJR|Ux97zgMUCwJO69VQ>? MWqyOVA1QDJ|Nh?=
DOHH-2 NXiwO2VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[5XVI1QCCq NWPjTnhCUUN3ME2xPU46yqEQvF2= MUGyOVA1QDJ|Nh?=
DOHH-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M363flczKGh? NEj6ZXFKSzVyPUZCpO69VQ>? NFv2T|EzPTB2OEKzOi=>
REH MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZVHZyOjRiaB?= MlfsTWM2OD1yLkCyO:Kh|ryP MlPwNlUxPDh{M{[=
REH NFHTVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxOFghcA>? NEHFRo5KSzVyPUCuNFE1yqEQvF2= M3H2XFI2ODR6MkO2
REH MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe3NkBp M37Vb2lEPTB;MD6wNVXDqM7:TR?= MXeyOVA1QDJ|Nh?=
HH MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvKNlQhcA>? NH7Ido9KSzVyPUGwOE44yqEQvF2= NXPjXmh1OjVyNEiyN|Y>
HH M2fQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DBNVQ5KGh? NH\jTYVKSzVyPUS4MlbDqM7:TR?= MYGyOVA1QDJ|Nh?=
HH NGjyWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXq3NkBp NITadIZKSzVyPUG0MlfDqM7:TR?= M1vSXVI2ODR6MkO2
HuT-78 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyOEBp MUfJR|UxRTlwM9Mg{txO NIm2O|YzPTB2OEKzOi=>
HuT-78 NYLCTodyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK1V3Y3PDhiaB?= NWnJTm9yUUN3ME20MlPDqM7:TR?= M3fZc|I2ODR6MkO2
HuT-78 NH7OZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jDNVczKGh? NUHrdVd2UUN3ME20MlLDqM7:TR?= MYqyOVA1QDJ|Nh?=
OPM-2 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGyOEBp MUHJR|UxRTJ2LkJCpO69VQ>? M4H3Z|I2ODR6MkO2
OPM-2 NHLxUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn3WVY1QCCq MXfJR|UxRTUEoN88US=> Mn\yNlUxPDh{M{[=
OPM-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp NXzhSIVJUUN3ME2xMlPDqM7:TR?= MVyyOVA1QDJ|Nh?=
RPMI-8226 NUG2NnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zHOlI1KGh? NUDBNnZEUUN3ME2xNFYvPsLizszN M1PJflI2ODR6MkO2
RPMI-8226 M{DlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXuOFghcA>? MkX0TWM2OD17MT6xxsDPxE1? MY[yOVA1QDJ|Nh?=
RPMI-8226 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NkBp NHzrPVJKSzVyPUG0MlnDqM7:TR?= NHzyXYMzPTB2OEKzOi=>
U-266 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHYNlQhcA>? MmjrTWM2OD16Nj6yxsDPxE1? M33pe|I2ODR6MkO2
U-266 M1;lXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:2SWt4PDhiaB?= M4DX[mlEPTB;NkiuOOKh|ryP NWe3[5h2OjVyNEiyN|Y>
U-266 NEPBR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\FSlczKGh? MV3JR|UxRTJ5LkVCpO69VQ>? NHjLNI4zPTB2OEKzOi=>
Kelly NI\3SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBc4luOC1zMDFOwG0> NF7oRW04OsLiaB?= NXT2OI96UUN3ME2xMlUyQMLizszN MVKyOVAxQDlyMB?=
SH-SY5Y  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTLRWxTOC1zMDFOwG0> M1PISlczyqCq MkTFTWM2OD1yLke1OOKh|ryPwrC= NYruVI1TOjVyMEi5NFA>
SK-N-AS MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjUdnQxNTFyIN88US=> NG\S[W44OsLiaB?= M2jxeWlEPTB;MT63NVLDqM7:TdMg MUeyOVAxQDlyMB?=
SK-N-DZ NEf0NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSwMVExKM7:TR?= NHHoNoM4OsLiaB?= NWH5dW9MUUN3ME21MlQ5PcLizszN MmSwNlUxODh7MEC=
HepG2 M2rKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi0POKhcA>? MXjEUXNQyqB? M3jnWWlEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= MYeyOFk6PjF|Nh?=
A549 M1\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KwS|Q5yqCq NEfiSIdFVVORwrC= M2LmTGlEPTB;MkSxMlnDqMLzwrCzNU4zO8LizszN MoLkNlQ6QTZzM{[=
MCF7 NWDHd3E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zFOFQ5yqCq MVTEUXNQyqB? MY\JR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= MWOyOFk6PjF|Nh?=
HL-60  NWC2[5Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ORWc4OsLiaB?= Mm\rTWM2OD1yLkGy5qCG|ryP NW\EZ2JvOjR7OUOwNVQ>
HL-60[R] NWW4bHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDSNXA4OsLiaB?= NVHXO4szUUN3ME2zMlEz6oDHzszN M3eybFI1QTl|MEG0
MIAPACA M4PuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q5TmdKPTB;MT6zJOKyKDBwMEOg{txO M4PZNlI1QTV|OEKx
MCF-7 M3\yUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLHTVUxRTBwMkWgxtEhOC5zIN88US=> NYLISlgzOjR7NUO4NlE>
HeLa NHTxOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnhc2d[T0l3ME2wMlY1KMLzIECuOEDPxE1? NFjZOXIzPDl3M{iyNS=>
MO59K  NFTLSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO0OGI4KGR? MUHJR|UxRTBwMUhihKXPxE1? M1z2elI1QTV|NU[x
MO59J NXr3SJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLWVGc4KGR? M3rGbmlEPTB;MD6x5qCG|ryP NEK4[YozPDl3M{W2NS=>
ME 180 NYOxR5kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\NcYE1QMLiaNMg NHT0NmhKSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= MV[yOFk2OzB{Nx?=
MCF-7 NFXCUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTpOI81QMLiaNMg NVThRoo1UUN3ME2yN{46KMLzIECuN-KBjc7:TR?= M{\VNVI1QTV|MEK3
HeLa MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37ZSlQ5yqCqwrC= NV;HdGFqUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= M1LUWFI1QTV|MEK3
MDA-MB-453 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXteHRrPDkEoHlCpC=> MnjPTWM2OD1zMj61JOKyKDBwOEZihKXPxE1? M{PlSVI1QTV|MEK3
MDA-MB-231 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fCTlQ5yqCqwrC= NYKxSIl6UUN3ME2yOE4zOiEEsTCyMlk16oDHzszN MlqzNlQ6PTNyMke=
PC-3 NEnuU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX4b2VEPDkEoHlCpC=> MoToTWM2OD1zND60JOKyKDNwMkRihKXPxE1? MUKyOFk2OzB{Nx?=
HT-29 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH63cZA1QMLiaNMg MXHJR|UxRTJzLkS1JOKyKDNwOEhihKXPxE1? MWCyOFk2OzB{Nx?=
BGC-823 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P4T|Q5yqCqwrC= NUnreWpHUUN3ME20N{44PCEEsTC1MlE{6oDHzszN MWqyOFc6Ozh5Nx?=
HeLa NY\l[2dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnLO4Y1QMLiaNMg Ml;RTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN MX:yOFc6Ozh5Nx?=
A549 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS0POKhcMLi M2fkcmlEPTB;MUO5MlU1KMLzIEeuNFXjiIYQvF2= NW\mUVN6OjR5OUO4O|c>
HK-2 M1\nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn33OFjDqGkEoB?= NE[zU5ZKSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= Mmr4NlQ4QTN6N{e=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
5% DMSO+30% PEG 300+H2O
15mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase信号経路図

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID